{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"Treatment-induced ADA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment-boosted ADA"}],"denoms":[{"counts":[{"groupId":"OG000","value":"433"}],"units":"Participants"}],"description":"Blood samples were collected at indicated timepoints to determine ADA. Treatment-induced ADA was defined as ADA positive post-baseline and not detected at baseline (negative or missing). Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following drug administration.","groups":[{"description":"Participants received T-DXd 5.4 mg/kg via IV infusion every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG000","title":"T-DXd"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The ADA population included all participants who received at least 1 dose of T-DXd and who had a non-missing ADA result at any time.","reportingStatus":"POSTED","timeFrame":"From Day 1 up to PCD of 18 March 2024 (maximum of approximately 43.85 months)","title":"Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab Deruxtecan","type":"SECONDARY","unitOfMeasure":"Participants"}